Previous 10 | Next 10 |
home / stock / trgnf / trgnf news
Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Arnaud Dubarry as Chief Financial Officer (CFO), effective January 1, 2024. Arnaud D...
2023-11-08 09:59:18 ET More on Transgene S.A. Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript Historical earnings data for Transgene S.A. Financial information for Transgene S.A. For further details see: Transgene reports Q3 results
Transgene continues to advance its innovative immunotherapy pipeline, with key clinical development catalysts expected in the next 12 months Financial visibility until the end of 2024 Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops v...
The Phase I Part B will evaluate the combination of BT-001 and pembrolizumab in solid tumors, including melanoma Regulatory News: Transgene (Euronext Paris: TNG) , a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent Internatio...
2023-09-20 15:08:03 ET Transgene SA (TRGNF) Q2 2023 Earnings Conference Call September 20, 2023 12:00 PM ET Company Participants Lucie Larguier - Head of Investor Relations Alessandro Riva - Chairman and Chief Executive Officer Jean-Philippe Del - Vice President ...
Promising data from ongoing clinical trials of neoantigen cancer vaccine TG4050 and HPV-positive cancer therapeutic vaccine TG4001 presented at key congresses in H1 2023 Immunogenicity clinical data from ongoing trials confirm mechanism of action of Transgene’s ther...
Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3 million (€ 14.0 million) as a result of the full disposal of its minority stake in a Chinese...
New immunological data assessed by tetramer staining confirms the induction of T cell responses in treated patients All trial patients treated with TG4050 monotherapy continue to remain in remission to date Transgene and NEC are preparing a Phase II trial to further demonstrate the potent...
TG4001 can induce de novo immune responses against HPV16 antigens E6 and E7 in patients with advanced HPV16-positive anogenital cancers Patients with complete objective response showed strong vaccine-induced immunoreactivity Transgene is preparing for a potentially registrational stud...
Presentations include new data further demonstrating the immune responses induced by TG4001 and recently updated results from the adjuvant Phase I trial of neoantigen vaccine TG4050 in head and neck cancer Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that desi...
News, Short Squeeze, Breakout and More Instantly...
Transgene S.A. Company Name:
TRGNF Stock Symbol:
OTCMKTS Market:
TG4050: Exciting Phase I data presented at AACR 2024 demonstrating first signs of clinical benefit in adjuvant setting for head and neck cancer Phase II part of randomized trial to start in coming weeks New clinical data expected on TG4001, TG6050 and BT-001 in H2 2024 Financial vis...
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shar...
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of 18.6 months. Phase II part of the trial to start enrolling patients in coming weeks. ...